Results 21 to 30 of about 42,119 (250)
Identification of Responders to Amiodarone: Subgroup Analysis of the EMIAT Study [PDF]
, 2003 Clinical trials often judge the efficacy of a new treatment by comparing the survival patterns of patients who are randomly assigned to undergo the new or a standard/placebo treatment.
Kehl, V. +7 more
core +1 more source
Clinical and Translational Science, 2022 Amiodarone and its main metabolite, desethylamiodarone (DEA), are highly distributed to serum lipoproteins such as very‐low‐density lipoprotein (VLDL) and low‐density lipoprotein (LDL), which are the carriers of triglyceride and cholesterol.
Naoaki Hashimoto +5 more
doaj +1 more source
Mitochondrial toxicity of drugs [PDF]
, 2008 The introduction of this thesis concentrates on the cellular energy supplier and an important instrument in mediating cell death, mitochondrion. First, an overview is given to explain the biochemical properties of this organelle.
Waldhauser, Katri Maria
core +1 more source
Diagnostics, 2022 Amiodarone hydrochloride is an antiarrhythmic drug, with proven efficacy in prevention and treatment of numerous arrhythmias, atrial fibrillation especially, or ventricular arrhythmias, with a long half-life (55–60 days). The increased risk of developing
Corina Eugenia Budin +6 more
doaj +1 more source
A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology [PDF]
, 2009 Aims ATI-2042 (budiodarone) is a chemical analogue of amiodarone with a half life of 7 h. It is electrophysiologically similar to amiodarone, but may not have metabolic and interaction side effects.
Camm, AJ +5 more
core +1 more source
Journal of the Belgian Society of Radiology, 2010 Background: A 65-year-old male patient presented with progressive shortness of breath over the past 3 months, recently even at rest. He neither complained about fever nor about chest pain. The laboratory findings were normal with only a slight increase in leucocytes. A significant restrictive ventilation disorder was noted on plethysmography.
Bley, T A, François, C J
openaire +5 more sources
Journal of the Formosan Medical Association, 2023 Background/purpose: Amiodarone increases exposure of direct oral anticoagulants (DOACs). We aimed to analyze the effects of concurrent amiodarone use on DOAC concentrations and clinical outcomes.
Shin-Yi Lin +7 more
doaj +1 more source
Drug interactions and hepatotoxicity of clopidogrel [PDF]
, 2010 Clopidogrel (Plavix¨) is an antiplatelet drug, which is clinically used in combination with aspirin to reduce cardiovascular events in patients undergoing percutaneous coronary intervention or in patients suffering from acute coronary syndromes ...
Zahno, Anja-Christina
core +1 more source
Endokrynologia Polska, 2015 Amiodarone, a benzofuranic iodine-rich antiarrhythmic drug, causes thyroid dysfunction in 15-20% of cases. Amiodarone can cause both hypothyroidism (AIH, amiodarone-induced hypothyroidism) and thyrotoxicosis (AIT, amiodarone-induced thyrotoxicosis). AIH is treated by L-thyroxin replacement and does not need amiodarone discontinuation.
Agata Jabrocka-Hybel +7 more
openaire +3 more sources
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022 Background Atrial and ventricular arrhythmias are commonly encountered in patients with advanced heart failure, with amiodarone being the most commonly used antiarrhythmic drug in continuous‐flow left ventricular assist device (CF‐LVAD) recipients.
Rakesh Gopinathannair +13 more
doaj +1 more source